Eli Lilly and Company
Eli Lilly Board Welcomes New Director and Announces Resignation
Summary
On November 19, 2024, Eli Lilly and Company announced that Jon Moeller has been elected to its board of directors, effective December 1, 2024, and that Karen Walker will resign from the board, effective December 31, 2024. Moeller, the Chairman, President, and CEO of Procter & Gamble, brings extensive leadership experience to the board and will serve on the Audit Committee and the Directors and Corporate Governance Committee. Walker, who has served on the board since 2018, will continue to collaborate with the company on certain digital commercial activities in 2025.
Profitelligence Alerts
Get alerts for LLY
Be first to know when Eli Lilly and Company files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Eli Lilly and Company
Eli Lilly and Company is a renowned pharmaceutical corporation that engages in the discovery, development, manufacturing, and marketing of pharmaceutical products worldwide. The company's core purpose is to create high-quality medications that address significant medical needs in areas such as oncology, immunology, neuroscience, and endocrinology. Eli Lilly is particularly noted for its pioneering work in diabetes care with products like insulin and for its innovative approach to treating complex health conditions. With a history dating back to 1876, the Indianapolis-based company blends scientific innovation with a commitment to improve patient outcomes. Eli Lilly’s role in the financial markets is significant due to its contributions to healthcare advancements and its influence on global pharmaceutical trends. The company's robust pipeline and emphasis on research and development underscore its potential to impact healthcare solutions and deliver sustainable growth. Its products and services are marketed globally, underlying its importance in the biopharmaceutical industry.
Official SEC Documents
Advertisement